ROCKET PHARMACEUTICALS, INC. (RCKT)
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business